Researcher
Anne Rogiers
- Keywords:Medicine
- Disciplines:Other basic sciences not elsewhere classified
Affiliations
- Laboratory for Medical and Molecular Oncology (Research group)
Member
From22 Mar 2021 → Today - Medical Oncology (Department)
Member
From1 Jan 2021 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → 20 Oct 2022 - Faculty of Medicine and Pharmacy (Faculty)
Member
From29 Sep 2017 → 8 Jul 2020 - Radiation Therapy (Department)
Member
From1 Apr 2015 → 31 Mar 2021
Projects
1 - 1 of 1
Publications
1 - 10 of 17
- Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg(2023)
Authors: Anne Rogiers, Laurence Willemot, Laura McDonald, Hilde Van Campenhout, Guy Berchem, Celine Jacobs, Nathalie Blockx, Andrée Rorive, B Neyns
- Health-state utilities in long-term advanced melanoma survivors comparable with the general population(2023)
Authors: M D Egeler, L V van de Poll-Franse, R Tissier, Anne Rogiers, M J Boers-Sonderen, A J van den Eertwegh, Geke A P Hospers, J W B de Groot, M J B Aarts, E Kapiteijn, et al.
Pages: 2517-2525 - Cancer-related cognitive impairment in non-CNS cancer patients(2022)
Authors: Charlotte Sleurs, Ali Amidi, Lisa M Wu, David Kiesl, Philipp Zimmer, Marie Lange, Anne Rogiers, Benedicte Giffard, Giulia Binarelli, Cindy Borghgraef, et al.
- Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors(2021)
Authors: André Manuel Da Silva Lopes, Sara Colomer-Lahiguera, Nuria Mederos Alfonso, Veronica Aedo-Lopez, Gilliosa Spurrier-Bernard, Lærke Kjær Tolstrup, Helle Pappot, Sandrine Aspeslagh, Anne Rogiers, B Neyns, et al.
Pages: 225-237 - A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab(2021)
Authors: Gil Awada, Yanina Jansen, Julia Katharina Schwarze, Jens Tijtgat, Lennert Hellinckx, Odrade Gondry, Sim Vermeulen, Sarah Warren, Kelly A Schats, Pieter-Jan van Dam, et al.
Pages: 1-18 - Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls(2021)
Authors: A H Boekhout, Anne Rogiers, K Jozwiak, M J Boers-Sonderen, A J van den Eertwegh, Geke A P Hospers, J W B de Groot, M J B Aarts, E Kapiteijn, A J Ten Tije, et al.
Pages: 69-77 - Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)(2020)
Authors: Gil Awada, Laila Ben Salama, Jennifer De Cremer, Julia Katharina Schwarze, Lydia Fischbuch, Laura Seynaeve, Stephanie Du Four, A Vanbinst, Alex Michotte, Hendrik Everaert, et al.
Pages: 1-12 - Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab(2020)
Authors: Anne Rogiers, Christophe Leys, Justine Lauwyck, Adrian Schembri, Gil Awada, Julia Katharina Schwarze, Jennifer De Cremer, Peter Theuns, Paul Maruff, Mark De Ridder, et al.
- Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study(2020)
Authors: Anne Rogiers, Christophe Leys, Jennifer De Cremer, Gil Awada, Adrian Schembri, Peter Theuns, Mark De Ridder, B Neyns
Pages: 3267-3278 - Health-related quality of life, psychological outcome and neurocognitive function in metastatic melanoma survivors treated with immune checkpoint inhibitors(2020)
Authors: Anne Rogiers, Mark De Ridder, B Neyns